Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer

Habeeb Majeed¹, Eitan Amir^{1

2}

Affiliations

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
² Department of Medicine, University of Toronto, Toronto, ON, Canada.

Editorial

Habeeb Majeed et al. J Thorac Dis. 2018 Apr.

. 2018 Apr;10(Suppl 9):S995-S998.

doi: 10.21037/jtd.2018.03.153.

Habeeb Majeed¹, Eitan Amir^{1

2}

¹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
² Department of Medicine, University of Toronto, Toronto, ON, Canada.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Mezquita L, et al. JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771. JAMA Oncol. 2018. PMID: 29327044 Free PMC article.

1. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;390:1853-62. 10.1016/S0140-6736(17)31601-X - DOI - PubMed
1. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015;373:1803-13. 10.1056/NEJMoa1510665 - DOI - PMC - PubMed
1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:1627-39. 10.1056/NEJMoa1507643 - DOI - PMC - PubMed
1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed
1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. 10.1016/S0140-6736(15)01281-7 - DOI - PubMed